1 |
Chang ST, Buswell JA. 2008. Development of the world mushroom industry: Applied mushroom biology and international mushroom organizations. Int J Med Mushrooms. 10:195-208.
DOI
|
2 |
Kawagishi H, Ando M, Mizuno T. 1990. Hericenone A and B as cytotoxic principles from the mushroom Hericium erinaceum. Tetrahedron Lett. 31:373-376.
DOI
ScienceOn
|
3 |
Kawagishi H, Ando M, Sakamoto H. 1991. Hericenone C, D and E, stimulators of nerve growth factor (NGF) synthesis, from the mushroom Hericium erinaceum. Tetrahedron Lett. 32:4561-4564.
DOI
ScienceOn
|
4 |
Yang BK, Park JB, Song CH. 2003. Hypolipidemic effect of an Exo-biopolymer produced from a submerged mycelial culture of Hericium erinaceus. Biosci Biotechnol Biochem. 67:1292-1298.
DOI
ScienceOn
|
5 |
Saito T, Aoki F, Hirai H, Inagaki T, Matsunaga Y, Sakakibara T, Sakemi S, Suzuki Y, Watanabe S, Suga O, Sujaku T, Smogowicz AA, Truesdell SJ, Wong JW, Nagahisa A, Kojima Y, Kojima N. 1998. Erinacine E as a kappa opioid receptor agonist and its new analogs from a basidiomycete, Hericium ramosum. J Antibiot (Tokyo). 51:983-990.
DOI
|
6 |
Stamets P. 2005. Notes on nutritional properties of culinary-medicinal mushrooms. Int J Med Mushrooms. 7:109-116.
|
7 |
Stein C, Millan M J, Shippenberg T S, Peter K, Herz A. 1989. Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. Pharmacol Exp Ther. 248:1269-1275.
|
8 |
Tuszynski MH, U HS, Amaral DG, Gage FH. 1990. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci. 10:3604-36014.
|
9 |
Watanabe H, Takano M, Umino A, Ito T, Ishikawa H, and Nakada M. 2007. Enantioselective total synthesis of (-)-erinacine B. Org Lett. 18:359-362.
|
10 |
Wong KH, Sabaratnam V, and Abdullah N. 2007. Activity of aqueous extracts of Lion's Mane Mushroom Hericium erinaceus (Bull.: Fr.) Pers. (Aphyllophoromycetideae) on the neural cell line NG108-15. Int J Med Mushrooms. 9:57-65.
DOI
|
11 |
Kawagishi H, Ando M, Shinba K. 1993. Chromans, hericenone F, G and H from the mushroom Hericium erinaceum. Phytochemistry. 32:175-178.
|
12 |
Kawagishi H, Shimada A, Shirai R. 1994. Erinacines A, B and C, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedron Lett. 35:1569-1572.
DOI
ScienceOn
|
13 |
Capsoni S, Giannotta S, Cattaneo A. 2002. Nerve growth factor and galatamine ameliorate early signs of neurodegeneration in anti-nerve growth factor mice. Proc Natl Acad Sci USA. 99:12423-12437.
|
14 |
Kenmoku H, Shimai T, Toyomasu T, Kato N, Sassa T, Erinacine Q. 2002. A new erinacine from Hericium erinaceum, and its biosynthetic route to erinacine C in the basidiomycete. Biosci Biotechnol Biochem. 66:571-575.
DOI
ScienceOn
|
15 |
Mattson MP. 1997. Neuroprotective signal transduction: relevance to stroke. Neurosci Biobehav Rev. 21:193-206.
DOI
ScienceOn
|
16 |
Mori K, Obara Y, Hirota M, Azumi Y, Kinugasa S, Inatomi S, Nakahata N. 2008. Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull. 31:1727-1732.
DOI
ScienceOn
|
17 |
Park YS, Lee HS, Won MH, Lee JH, Lee SY, Lee HY. 2002. Effect of an exo-polysaccharide from the culture broth of hericium erinaceus on enhancement of growth and differentiation of rat adrenal nerve cells. Cytotechnology. 39:155-162.
DOI
ScienceOn
|
18 |
Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. 2009. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 23:367-372.
DOI
ScienceOn
|
19 |
Nagano M, Shimizu K, Kondo R, Hayashi C, Sato D, Kitagawa K, Ohnuki K. 2010. Reduction of depression and anxiety by 4 weeks Hericium erinaceus intake. Biomed Res. 31:231-237.
DOI
|
20 |
Obara Y, Nakahata N. 2002. The signaling pathway of neurotropic factor. Drug News and Perspect. 15:290-298.
DOI
ScienceOn
|
21 |
Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M, Kameyama T, Furukawa Y, Hayashi K, Nabeshima T. 1997. Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer's disease. Behav Brain Res. 83:117-122.
DOI
ScienceOn
|